Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

Saiko Kurosawa, Kumi Oshima, Takuhiro Yamaguchi, Atsumi Yanagisawa, Takahiro Fukuda, Heiwa Kanamori, Takehiko Mori, Satoshi Takahashi, Tadakazu Kondo, Akio Kohno, Koichi Miyamura, Yukari Umemoto, Takanori Teshima, Shuichi Taniguchi, Takuya Yamashita, Yoshihiro Inamoto, Yoshinobu Kanda, Shinichiro Okamoto, Yoshiko Atsuta

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Knowing the impact of chronic graft-versus-host disease (GVHD) on quality of life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study to examine the relationship between patient-reported QoL as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and visual analogue scale (VAS) and chronic GVHD defined by the National Institutes of Health (NIH) criteria. Recipients of allo-HCT for hematologic disease between 1995 and 2009 aged ≥ 16 years at transplant and ≥20 years at the time of the survey who were relapse-free were eligible. A total of 1140 pairs of patient and physician questionnaires were included in the analysis. By NIH global severity score, QoL scores in all aspects were significantly lower in patients with higher global and organ-specific severity grades, independent of background variables. Compared with patients without GVHD symptoms, those with mild symptoms had impaired physical and general QoL according to global severity score and organ-specific scores except for the genital tract. Mild symptoms in the lungs, gastrointestinal tract, and joints and fascia were associated with clinically meaningful deterioration of physical QoL. VAS scores provided by physicians were generally higher than those provided by patients. Differences between scores reported by patients and physicians were larger for patients with no or mild GVHD symptoms. Our findings based on more than 1000 long-term survivors after HCT enabled us to identify a target of care, informing survivorship care protocols to improve post-transplantation QoL.

Original languageEnglish
JournalBiology of Blood and Marrow Transplantation
DOIs
Publication statusAccepted/In press - 2017

Fingerprint

Cell Transplantation
Graft vs Host Disease
Quality of Life
Hematopoietic Stem Cell Transplantation
National Institutes of Health (U.S.)
Physicians
Visual Analog Scale
Transplants
Survivors
Bone Neoplasms
Hematologic Diseases
Fascia
Critical Care
Health Surveys
Gastrointestinal Tract
Survival Rate
Cross-Sectional Studies
Joints
Transplantation
Bone Marrow

Keywords

  • Allogeneic hematopoietic cell transplantation
  • Graft-versus-host disease
  • Long-term follow-up
  • National Institutes of Health criteria
  • Proxy
  • Quality of life

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. / Kurosawa, Saiko; Oshima, Kumi; Yamaguchi, Takuhiro; Yanagisawa, Atsumi; Fukuda, Takahiro; Kanamori, Heiwa; Mori, Takehiko; Takahashi, Satoshi; Kondo, Tadakazu; Kohno, Akio; Miyamura, Koichi; Umemoto, Yukari; Teshima, Takanori; Taniguchi, Shuichi; Yamashita, Takuya; Inamoto, Yoshihiro; Kanda, Yoshinobu; Okamoto, Shinichiro; Atsuta, Yoshiko.

In: Biology of Blood and Marrow Transplantation, 2017.

Research output: Contribution to journalArticle

Kurosawa, S, Oshima, K, Yamaguchi, T, Yanagisawa, A, Fukuda, T, Kanamori, H, Mori, T, Takahashi, S, Kondo, T, Kohno, A, Miyamura, K, Umemoto, Y, Teshima, T, Taniguchi, S, Yamashita, T, Inamoto, Y, Kanda, Y, Okamoto, S & Atsuta, Y 2017, 'Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease', Biology of Blood and Marrow Transplantation. https://doi.org/10.1016/j.bbmt.2017.06.011
Kurosawa, Saiko ; Oshima, Kumi ; Yamaguchi, Takuhiro ; Yanagisawa, Atsumi ; Fukuda, Takahiro ; Kanamori, Heiwa ; Mori, Takehiko ; Takahashi, Satoshi ; Kondo, Tadakazu ; Kohno, Akio ; Miyamura, Koichi ; Umemoto, Yukari ; Teshima, Takanori ; Taniguchi, Shuichi ; Yamashita, Takuya ; Inamoto, Yoshihiro ; Kanda, Yoshinobu ; Okamoto, Shinichiro ; Atsuta, Yoshiko. / Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease. In: Biology of Blood and Marrow Transplantation. 2017.
@article{062520e13dd042ceafc0e8117d80057e,
title = "Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease",
abstract = "Knowing the impact of chronic graft-versus-host disease (GVHD) on quality of life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study to examine the relationship between patient-reported QoL as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and visual analogue scale (VAS) and chronic GVHD defined by the National Institutes of Health (NIH) criteria. Recipients of allo-HCT for hematologic disease between 1995 and 2009 aged ≥ 16 years at transplant and ≥20 years at the time of the survey who were relapse-free were eligible. A total of 1140 pairs of patient and physician questionnaires were included in the analysis. By NIH global severity score, QoL scores in all aspects were significantly lower in patients with higher global and organ-specific severity grades, independent of background variables. Compared with patients without GVHD symptoms, those with mild symptoms had impaired physical and general QoL according to global severity score and organ-specific scores except for the genital tract. Mild symptoms in the lungs, gastrointestinal tract, and joints and fascia were associated with clinically meaningful deterioration of physical QoL. VAS scores provided by physicians were generally higher than those provided by patients. Differences between scores reported by patients and physicians were larger for patients with no or mild GVHD symptoms. Our findings based on more than 1000 long-term survivors after HCT enabled us to identify a target of care, informing survivorship care protocols to improve post-transplantation QoL.",
keywords = "Allogeneic hematopoietic cell transplantation, Graft-versus-host disease, Long-term follow-up, National Institutes of Health criteria, Proxy, Quality of life",
author = "Saiko Kurosawa and Kumi Oshima and Takuhiro Yamaguchi and Atsumi Yanagisawa and Takahiro Fukuda and Heiwa Kanamori and Takehiko Mori and Satoshi Takahashi and Tadakazu Kondo and Akio Kohno and Koichi Miyamura and Yukari Umemoto and Takanori Teshima and Shuichi Taniguchi and Takuya Yamashita and Yoshihiro Inamoto and Yoshinobu Kanda and Shinichiro Okamoto and Yoshiko Atsuta",
year = "2017",
doi = "10.1016/j.bbmt.2017.06.011",
language = "English",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Quality of Life after Allogeneic Hematopoietic Cell Transplantation According to Affected Organ and Severity of Chronic Graft-versus-Host Disease

AU - Kurosawa, Saiko

AU - Oshima, Kumi

AU - Yamaguchi, Takuhiro

AU - Yanagisawa, Atsumi

AU - Fukuda, Takahiro

AU - Kanamori, Heiwa

AU - Mori, Takehiko

AU - Takahashi, Satoshi

AU - Kondo, Tadakazu

AU - Kohno, Akio

AU - Miyamura, Koichi

AU - Umemoto, Yukari

AU - Teshima, Takanori

AU - Taniguchi, Shuichi

AU - Yamashita, Takuya

AU - Inamoto, Yoshihiro

AU - Kanda, Yoshinobu

AU - Okamoto, Shinichiro

AU - Atsuta, Yoshiko

PY - 2017

Y1 - 2017

N2 - Knowing the impact of chronic graft-versus-host disease (GVHD) on quality of life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study to examine the relationship between patient-reported QoL as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and visual analogue scale (VAS) and chronic GVHD defined by the National Institutes of Health (NIH) criteria. Recipients of allo-HCT for hematologic disease between 1995 and 2009 aged ≥ 16 years at transplant and ≥20 years at the time of the survey who were relapse-free were eligible. A total of 1140 pairs of patient and physician questionnaires were included in the analysis. By NIH global severity score, QoL scores in all aspects were significantly lower in patients with higher global and organ-specific severity grades, independent of background variables. Compared with patients without GVHD symptoms, those with mild symptoms had impaired physical and general QoL according to global severity score and organ-specific scores except for the genital tract. Mild symptoms in the lungs, gastrointestinal tract, and joints and fascia were associated with clinically meaningful deterioration of physical QoL. VAS scores provided by physicians were generally higher than those provided by patients. Differences between scores reported by patients and physicians were larger for patients with no or mild GVHD symptoms. Our findings based on more than 1000 long-term survivors after HCT enabled us to identify a target of care, informing survivorship care protocols to improve post-transplantation QoL.

AB - Knowing the impact of chronic graft-versus-host disease (GVHD) on quality of life (QoL) after allogeneic hematopoietic stem cell transplantation (allo-HCT) by GVHD type and severity is critical for providing care to transplant survivors. We conducted a cross-sectional questionnaire study to examine the relationship between patient-reported QoL as measured by the Medical Outcomes Study 36-Item Short-Form Health Survey, Functional Assessment of Cancer Therapy-Bone Marrow Transplant, and visual analogue scale (VAS) and chronic GVHD defined by the National Institutes of Health (NIH) criteria. Recipients of allo-HCT for hematologic disease between 1995 and 2009 aged ≥ 16 years at transplant and ≥20 years at the time of the survey who were relapse-free were eligible. A total of 1140 pairs of patient and physician questionnaires were included in the analysis. By NIH global severity score, QoL scores in all aspects were significantly lower in patients with higher global and organ-specific severity grades, independent of background variables. Compared with patients without GVHD symptoms, those with mild symptoms had impaired physical and general QoL according to global severity score and organ-specific scores except for the genital tract. Mild symptoms in the lungs, gastrointestinal tract, and joints and fascia were associated with clinically meaningful deterioration of physical QoL. VAS scores provided by physicians were generally higher than those provided by patients. Differences between scores reported by patients and physicians were larger for patients with no or mild GVHD symptoms. Our findings based on more than 1000 long-term survivors after HCT enabled us to identify a target of care, informing survivorship care protocols to improve post-transplantation QoL.

KW - Allogeneic hematopoietic cell transplantation

KW - Graft-versus-host disease

KW - Long-term follow-up

KW - National Institutes of Health criteria

KW - Proxy

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=85026647553&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026647553&partnerID=8YFLogxK

U2 - 10.1016/j.bbmt.2017.06.011

DO - 10.1016/j.bbmt.2017.06.011

M3 - Article

C2 - 28669922

AN - SCOPUS:85026647553

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

ER -